Four years after ICU admission, mortality remains strikingly high in ventilated COVID-19 ARDS patients, and many survivors continue to struggle with fatigue, insomnia, functional decline, and reduced ...

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. For patients with refractory acute respiratory distress syndrome (ARDS) due to COVID-19 infections, ...

Deaths from acute respiratory distress syndrome (ARDS) and sepsis spiked in the US during the COVID pandemic, and subsequently declined, according to new data presented at the American College of ...

Acute respiratory distress syndrome, or ARDS, is a condition that most commonly occurs in the setting of a lung infection such as COVID-19. “In ARDS, the barrier between the blood vessels and air sacs ...

As for whether the trial established that simvastatin is beneficial, the trial was stopped early because of a low likelihood of reaching prespecified stopping criteria, as a result of decreasing ...

Please provide your email address to receive an email when new articles are posted on . Researchers observed high lysolipid levels in those with acute respiratory distress syndrome (ARDS), which may ...

SARS-CoV-2, the virus that causes COVID-19, can damage the heart even without directly infecting the heart tissue, a new study has found. The research specifically looked at damage to the hearts of ...

Inhaled sevoflurane significantly reduced ventilator-free days and 90-day survival versus IV propofol in moderate to severe ARDS. Inhaled volatile sedatives grew in popularity for prolonged use in ...

Xintela (XINT) announces that the Japanese Patent Office (JPO) has granted a patent covering the company's stem cell product XSTEM® for the treatment of acute respiratory distress syndrome (ARDS) and ...

Drawing from research on sepsis and complement biology, they developed the monoclonal antibody vilobelimab to block overactive inflammatory responses in patients with severe inflammatory diseases ...